Drug Detail:My way (Levonorgestrel emergency contraceptive [ lee-voe-nor-jes-trel ])
Drug Class: Contraceptives
Highlights of Prescribing Information
These highlights do not include all the information needed to use My Way safely and effectively. See full prescribing information for My Way.
My Way (Levonorgestrel) TABLET for ORAL use.
Initial U.S. Approval: 1982
Indications and Usage for My Way Tablets
My way is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. My way is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. My way is not intended for routine use as a contraceptive. (1)
My Way Tablets Dosage and Administration
One tablet taken orally as soon as possible within 72 hours after unprotected intercourse. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. (2)
Dosage Forms and Strengths
1.5 mg tablet (3)
Contraindications
Known or suspected pregnancy (4)
Warnings and Precautions
- Ectopic pregnancy: Women who become pregnant or complain of lower abdominal pain after taking My way should be evaluated for ectopic pregnancy. (5.1)
- My way is not effective in terminating an existing pregnancy. (5.2)
- Effect on menses: My way may alter the next expected menses. If menses is delayed beyond 1 week, pregnancy should be considered. (5.3)
- STI/HIV: My way does not protect against STI/HIV. (5.4)
Adverse Reactions/Side Effects
The most common adverse reactions (≥10%) in clinical trials included heavier menstrual bleeding (31%), nausea (14%), lower abdominal pain (13%), fatigue (13%), headache (10%), and dizziness (10%). (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact at or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Use In Specific Populations
- Nursing Mothers: Small amounts of progestin pass into the breast milk of nursing women taking progestin-only pills for long-term contraception, resulting in detectable steroid levels in infant plasma. (8.3)
- My way is not intended for use in premenarcheal (8.4) or postmenopausal females (8.5).
See 17 for PATIENT COUNSELING INFORMATION.
Revised: 2/2013
Related/similar drugs
levonorgestrel, Plan B One-Step, ulipristal, ethinyl estradiol / levonorgestrel, ella, Morning AfterFull Prescribing Information
1. Indications and Usage for My Way Tablets
My Way is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse.
My Way is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. My Way is not indicated for routine use as a contraceptive.
2. My Way Tablets Dosage and Administration
Take My Way orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. My Way can be used at any time during the menstrual cycle.
If vomiting occurs within two hours of taking the tablet, consideration should be given to repeating the dose.
3. Dosage Forms and Strengths
The My Way tablet is supplied as a white to off-white, round, flat tablets containing 1.5 mg of levonorgestrel and debossed with “NL 620” on one side and plain on the other side.
5. Warnings and Precautions
5.1 Ectopic Pregnancy
Ectopic pregnancies account for approximately 2% of all reported pregnancies. Up to 10% of pregnancies reported in clinical studies of routine use of progestin-only contraceptives are ectopic.
A history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. Healthcare providers, however, should consider the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain after taking My Way. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking My Way.
5.3 Effects on Menses
Some women may experience spotting a few days after taking My Way. Menstrual bleeding patterns are often irregular among women using progestin-only oral contraceptives and women using levonorgestrel for postcoital and emergency contraception.
If there is a delay in the onset of expected menses beyond 1 week, consider the possibility of pregnancy.
6. Adverse Reactions/Side Effects
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
My Way was studied in a randomized, double-blinded multicenter clinical trial. In this study, all women who had received at least one dose of study medication were included in the safety analysis: 1,379 women in the My Way group, and 1,377 women in the Plan B group (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). The mean age of women given My Way was 27 years. The racial demographic of those enrolled was 54% Chinese, 12% Other Asian or Black, and 34% were Caucasian in each treatment group. 1.6% of women in the My Way group and 1.4% in Plan B group were lost to follow-up.
The most common adverse events (>10%) in the clinical trial for women receiving My Way included heavier menstrual bleeding (30.9%), nausea (13.7%), lower abdominal pain (13.3%), fatigue (13.3%), and headache (10.3%). Table 1 lists those adverse events that were reported in > 4% of My Way users.
Most Common Adverse Events (MedDRA) | |
Heavier menstrual bleeding | 30.9 |
Nausea | 13.7 |
Lower abdominal pain | 13.3 |
Fatigue | 13.3 |
Headache | 10.3 |
Dizziness | 9.6 |
Breast tenderness | 8.2 |
Delay of menses (> 7 days) | 4.5 |
7. Drug Interactions
Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the effectiveness of progestin-only pills. (7)
Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the plasma concentrations of progestins, and may decrease the effectiveness of progestin-only pills. Some drugs or herbal products that may decrease the effectiveness of progestin-only pills include:
- barbiturates
- bosentan
- carbamazepine
- felbamate
- griseofulvin
- oxcarbazepine
- phenytoin
- rifampin
- St. John’s wort
- topiramate
Significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of co-administration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.
Consult the labeling of all concurrently used drugs to obtain further information about interactions with progestin-only pills or the potential for enzyme alterations.
8. Use In Specific Populations
8.3 Nursing Mothers
In general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the health, growth, or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers taking progestin-only pills for long-term contraception, resulting in detectable steroid levels in infant plasma.
8.4 Pediatric Use
Safety and efficacy of progestin-only pills for long-term contraception have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of My Way emergency contraception before menarche is not indicated.
8.6 Race
No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both Plan B and the Yuzpe regimen (another form of emergency contraception). There was a non-statistically significant increased rate of pregnancy among Chinese women in the My Way trial. The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown.
MY WAY
levonorgestrel tablet |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
Labeler - GAVIS Pharmaceuticals, LLC. (829838551) |
Registrant - GAVIS Pharmaceuticals, LLC. (829838551) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Novel Laboratories, Inc. | 793518643 | ANALYSIS(43386-620) , MANUFACTURE(43386-620) |